Evidence map›Paper›PMID 23021333›Full record

ArticleJournal of the American College of Cardiology2012

Neuropeptide Y (NPY): genetic variation in the human promoter alters glucocorticoid signaling, yielding increased NPY secretion and stress responses.

Kuixing Zhang, Fangwen Rao, Jose Pablo Miramontes-Gonzalez, C Makena Hightower, Brian Vaught, Yuhong Chen, Tiffany A Greenwood, Andrew J Schork, Lei Wang, Manjula Mahata and 14 more

Erratum issuedOpen access · greenAbstract readComparative Study
In one paragraph

Article in Journal of the American College of Cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Understanding resilience.Frontiers in behavioral neuroscience · 2013
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

24 authors at 5 institutions in 3 countries.

Kuixing ZhangDepartment of Medicine and Institute for Genomic Medicine, University of California at San Diego, San Diego, California, USA.
Fangwen Rao
Jose Pablo Miramontes-Gonzalez
C Makena Hightower
Brian Vaught
Yuhong Chen
Tiffany A Greenwood
Andrew J Schork
Lei Wang
Manjula Mahata
Mats Stridsberg
Srikrishna Khandrika
Nilima Biswas
Maple M Fung
Jill Waalen
Rita P Middelberg
Andrew C Heath
Grant W Montgomery
Nicholas G Martin
John B Whitfield
Dewleen G Baker
Nicholas J Schork
Caroline M Nievergelt
Daniel T O'Connor
University of California San Diego · USQIMR Berghofer Medical Research Institute · AUScripps Research Institute · USGenomatica (United States) · USUppsala University · SE

Funding

Trafficking of catecholamine storage vesicle proteinsP01HL058120 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI O'CONNOR, DANIEL T · 1999 to 2009
$18.5M
San Diego EXPORT Comprehensive NCMHD Research CenterP60MD000220 · NIMHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VILLARREAL, FRANCISCO · 2002 to 2011
$11.0M
Genomic Predictors of Combat Stress Vulnerability and ResilienceR01MH093500 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIEVERGELT, CAROLINE M · 2011 to 2013
$2.7M
GENE-ENVIRONMENT INTERPLAY IN ALCOHOLISMK05AA017688 · NIAAA · WASHINGTON UNIVERSITY · PI HEATH, ANDREW C. · 2008 to 2017
$1.9M
Hypertensive kidney disease: Novel pathogenic and therapeutic pathwayR01DK094894 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VAINGANKAR, SUCHETA M · 2012 to 2015
$1.4M
San Diego Clinical and Translational Research InstituteKL2TR000099 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2014
$1.1M
NCATS NIH HHS KL2 TR000099NHLBI NIH HHS P01 HL058120NIAAA NIH HHS K05 AA017688NIDDK NIH HHS R01 DK094894NIMHD NIH HHS P60 MD000220NIMH NIH HHS R01 MH093500
6 · The paper itself

Abstract

objectivesThis study sought to understand whether genetic variation at the Neuropeptide Y (NPY) locus governs secretion and stress responses in vivo as well as NPY gene expression in sympathochromaffin cells.

backgroundThe NPY is a potent pressor peptide co-released with catecholamines during stress by sympathetic axons. Genome-wide linkage on NPY secretion identified a LOD (logarithm of the odds ratio) peak spanning the NPY locus on chromosome 7p15.

methodsOur approach began with genomics (linkage and polymorphism determination), extended into NPY genetic control of heritable stress traits in twin pairs, established transcriptional mechanisms in transfected chromaffin cells, and concluded with observations on blood pressure (BP) in the population.

resultsSystematic polymorphism tabulation at NPY (by re-sequencing across the locus: promoter, 4 exons, exon/intron borders, and untranslated regions; on 2n = 160 chromosomes of diverse biogeographic ancestries) identified 16 variants, of which 5 were common. We then studied healthy twin/sibling pairs (n = 399 individuals), typing 6 polymorphisms spanning the locus. Haplotype and single nucleotide polymorphism analyses indicated that proximal promoter variant ∇-880Δ (2-bp TG/-, Ins/Del, rs3037354) minor/Δ allele was associated with several heritable (h(2)) stress traits: higher NPY secretion (h(2) = 73 ± 4%) as well as greater BP response to environmental (cold) stress, and higher basal systemic vascular resistance. Association of ∇-880Δ and plasma NPY was replicated in an independent sample of 361 healthy young men, with consistent allelic effects; genetic variation at NPY also associated with plasma NPY in another independent series of 2,212 individuals derived from Australia twin pairs. Effects of allele -880Δ to increase NPY expression were directionally coordinate in vivo (on human traits) and in cells (transfected NPY promoter/luciferase reporter activity). Promoter -880Δ interrupts a novel glucocorticoid response element motif, an effect confirmed in chromaffin cells by site-directed mutagenesis on the transfected promoter, with differential glucocorticoid stimulation of the motif as well as alterations in electrophoretic mobility shifts. The same -880Δ allele also conferred risk for hypertension and accounted for approximately 4.5/approximately 2.1 mm Hg systolic BP/diastolic BP in a population sample from BP extremes.

conclusionsWe conclude that common genetic variation at the NPY locus, especially in proximal promoter ∇-880Δ, disrupts glucocorticoid signaling to influence NPY transcription and secretion, raising systemic vascular resistance and early heritable responses to environmental stress, eventuating in elevated resting BP in the population. The results point to new molecular strategies for probing autonomic control of the human circulation and ultimately susceptibility to and pathogenesis of cardiovascular and neuropsychiatric disease states.

Indexed as

Gene Expression RegulationGenetic Predisposition to DiseaseAdolescentAdultAgedAged, 80 and overAllelesDNAElectrophoretic Mobility Shift AssayFemaleGenetic VariationGenotypeHumansHypertensionMaleMiddle AgedDNANeuropeptide YReceptors, Glucocorticoid

Identifiers

PMID23021333
PMCPMC3687554
OpenAlexW5081543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.